| CEO Name | Douglas S. Ingram |
| Nationality | United States |
| Net Worth Estimation | $80 million |
Douglas S. Ingram's estimated net worth of around $80 million stems primarily from his executive compensation, equity holdings, and stock options as CEO of Sarepta Therapeutics, a leading biotechnology company focused on genetic medicines for rare diseases. His financial profile is also influenced by decades of leadership roles in the pharmaceutical industry, including previous executive positions at Allergan.
Douglas S. Ingram, CEO of Sarepta Therapeutics, has an estimated net worth of $80,000,000, which is the maximum in the biotechnology business category listed. His net worth represents 100% of the maximum and 800% of the minimum estimated CEO net worth in this sector.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Douglas S. Ingram Performance in Sarepta Therapeutics
Douglas S. Ingram, CEO of Sarepta Therapeutics, demonstrates strategic leadership focused on accelerating innovative gene therapies for rare neuromuscular diseases. His decisive approach to investment in research and product pipeline expansion has significantly enhanced the company's market position and financial performance. Under Ingram's leadership, Sarepta has achieved critical regulatory milestones, driving growth and establishing itself as a leader in precision genetic medicine.
Latest News
Sarepta Therapeutics Faces Clinical Trial Setbacks Amid CEO Doug Ingram's Leadership
Sarepta's confirmatory trials for Duchenne muscular dystrophy drugs recently failed to meet primary endpoints, impacting revenue and stock value; CEO Doug Ingram defended the company's transparency and strategic decisions despite challenges including a patient fatality unrelated to ongoing programs. The company recently completed a financial restructuring and continues development of gene therapies and siRNA portfolios with optimism despite current trial disappointments.
Source: http://www.biopharmadive.com/news/sarepta-duchenne-vyondys-amondys-essence-confirm-study-results/804577/